WE HEAL CHRONIC WOUNDS

WITH OUR MULTI-TARGET CELL AND GENE THERAPY PLATFORM

Chronic wounds are non-healing wounds that fail to progress through the normal stages of wound healing within a reasonable time, usually six weeks, and that may never fully heal. Chronic wounds can affect any part of the body, but are most common in the lower extremities, particularly the feet, ankles and legs.

Chronic wounds are a major public health problem. Between 1% and 2% of the world population will experience a chronic wound at some point in their lives; this represents between 123 and 246 million people worldwide and 15 million every year! Chronic wounds can be caused by a variety of factors, including diabetes and obesity, peripheral artery disease, or venous insufficiency. Chronic wounds, such as Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs), can be very painful and debilitating; they can lead to serious complications such as infections, amputations and even death.

BURDEN OF CHRONIC WOUNDS

Burden of chronic wounds
Burden of chronic wounds

Incremental improvement to chronic wound treatment is insufficient. Current wound care practices often lack precision and consistency, leading to ineffective treatment and prolonged healing times. Each year, thousands of patients undergo preventable amputations as a result of ineffective management of DFUs or VLUs. The psychological, physical, and financial burden of living with chronic wounds affects both patients and their families. The burden of chronic wounds is significant in terms of human suffering and economic cost.

INTRODUCING AUP-16

OUR SOLUTION FOR THE TREATMENT OF CHRONIC WOUNDS

We believe that, when treating chronic wounds, one needs to hit multiple targets to be disease-modifying. Very few companies or products can claim to be truly multi-target. Carefully designed and developed pharmaceutical products, such as our Advanced Therapy Medicinal Product (ATMP) AUP-16, will make the difference for patients. Our unique multi-target ATMP approach promotes the healing of the wound by promoting tissue regeneration and releasing active biological therapeutic agents within the wound itself.

One Active Pharmaceutical Ingredient (API) product with the benefits of four therapeutics.

AUP-16 is a safe and effective recombinant live biotherapeutic product that features a patented active bacterial vector. AUP-16 includes four therapies in one product:

1. COLONY STIMULATING
FACTOR 1 (h-CSF-1)

A hematopoietic growth factor involved in the proliferation, differentiation, and survival of monocytes, macrophages, and bone marrow progenitor cells.

2. FIBROBLAST GROWTH FACTOR (h-FGF-2)

A clinically used growth factor and signaling protein involved in cell proliferation and tissue repair.

3. INTERLEUKIN 4
(h-IL-4)

A potent anti-inflammatory M2 cytokine that promotes regeneration.

4. LACTOCOCCUS
CREMORIS

A non-pathogenic lactic acid bacteria that acts as a bioreactor in the tissue, producing human therapeutic proteins in the wound. AUP-16 takes advantage of the safe, living bioreactor to produce proteins FGF-2, IL-4 and CSF-1.

AUP-16 is a topical treatment created using a genetically modified Lactococcus cremoris bacteria. AUP-16 promotes healing by producing three human therapeutic proteins that (1) improve cell activation and conversion to anti-inflammatory phenotype, (2) increase fibroblast proliferation, and (3) promote angiogenesis and granulation tissue formation. 

The continuous production of the three human therapeutic proteins h-CSF-1, h-FGF-2 and h-IL-4 by the active vector Lactococcus cremoris at the site of the wound, results in our unique 4-in-1 combination biological treatment which is provided as one API.

Illustration of Aurealis Therapeutics AUP-16 indication

AUP-16 provides multi-therapy in one product, it is not a combination product. Thanks to its multi-target approach, AUP-16 is able to reduce inflammation promote proliferation and angiogenesis, and accelerate remodeling.  All in one product.

Our therapy, AUP-16, is created under Good Manufacturing Practice conditions and analyzed using state-of-the-art methods to ensure identity, potency, consistency, and safety. 

AUP-16 has the power to accelerate and provide complete wound healing, avoiding amputations. This remarkable advancement is ideal for patients who only achieve partial response to wound care dressings and treatment of symptoms.

As opposed to the existing standard of care, AUP-16 promotes tissue regeneration in the wound to activate healing from within.

AUP-16 RECEIVED PRIME STATUS FROM THE EUROPEAN MEDICINES AGENCY

In February 2024, the Committee for Medicinal products for Human Use (CHMP) and the European Medicines Agency (EMA) have acknowledge that non-healing Diabetic Foot Ulcers (nhDFU) are a potentially life-threatening condition with unmet need for novel therapies, and that AUP-16 has the potential to address this unmet need.

First Aurealis Therapeutics product candidate to receive PRIME designation by EMA for enhanced regulatory support facilitating the clinical development of multi-target cell and gene therapy candidate AUP-16 in the treatment of nhDFU.

PRIME designation follows positive data for 16 patients from Phase-1 first-in-human study showing a dose-dependent improvement in wound closure, 67% and 83% wound closure at 3 and 6 months respectively, demonstrating the potential to address the unmet medical need in nhDFU.

Read all details here. 

HIGHLIGHTS OF AUP-16

FOUR-IN-ONE

cell and gene therapy that stimulates endogenous tissue regeneration

BIOAVAILABLE

protein production at the site of the injury

TOPICAL APPLICATION

makes it easy to  administer

SAFE

modified food-grade bacteria

LEARN ABOUT AUP-16 MODE OF ACTION

SCIENTIFIC PUBLICATIONS ABOUT AUP-16

November 2023 | ISPOR Heath Economic Conference abstract and poster

Aurealis Therapeutics presented an abstract and a poster at ISPO Health Economic Conference titled: Cost-effectiveness of a multi-targeting bacterial gene therapy (AUP-16) at healing a Diabetic Foot Ulcer when compared to the current standard of care. Access the poster and the article here.

October 2023 | 14th International Symposium on Lactic Acid Bacteria poster

Aurealis Therapeutics presented a poster at the 14th International Symposium on Lactic Acid Bacteria titled: Multi-target bacterial gene therapy for chronic wounds and cancer. Access the poster here.

May 2023 | EWMA Conference Milan 2023 oral presentation

Aurealis Therapeutics gave an oral presentation at the European Wound Management Association (EWMA) Conference Milan 2023 titled: 4-in-1 live biotherapeutic Gene Therapy Medicinal Product (GTMP) accelerates healing of Diabetic Foot Ulcers (DFUs): a first-in-human, phase 1 clinical study. Access the oral presentation here.

February 2022 | PLOS-One scientific article

Aurealis Therapeutics published a scientific article in the PLOS-One journal titled: 4-in-1 Combination therapy using Lactococcus lactis expressing three therapeutic proteins for the treatment of chronic non-healing wounds. Access the article here.

May 2018 | EWMA Conference Krakow 2018 poster

Aurealis Therapeutics presented a poster at the European Wound Management Association (EWMA) Conference Krakow 2018 titled: Therapeutic use of Lactococcus lactis bacteria to produce proteins locally in diseased tissues of chronic wounds. Access the oral presentation here.

CLINICAL TRIALS IN CHRONIC WOUNDS

AUP-16 FOR CHRONIC WOUNDS

PHASE 1 CLINICAL STUDY IN DFU (COMPLETED)

83% of the patients achieved complete healing. No healed ulcer recurred after 12 months follow-up.

In June 2022, we successfully completed the Phase 1 study (NCT04281992 and EudraCT 2018-003415-22) in non-healing Diabetic Foot Ulcer patients with our lead product AUP-16. The last patient last visit (LPLV) was on 20th March 2023. Results were presented during EWMA 2023 conference in Milan and will be published in 2024.

Aurealis Therapeutics technology platform works in real life: non-healing diabetic wounds heal. Clinical results: 83% of patients reached complete healing, no healed ulcer recurred after 12 months follow-up.

More details about our Phase 1 Clinical Study:
NIH National Library of Medicine record

More details about our Phase 1 Clinical Study:
EU Clinical Trials Register

PHASE 2 CLINICAL STUDY IN DFU (ONGOING)

AUP-16 DIAMEND Phase 2 RCT in Diabetic Foot Ulcer ongoing in Germany, Italy and Poland.

AUP-16 Phase 2 study (NCT06111183 and EudraCT 2022-502048-10-00) in DFU received CTA approval in May 2023; the first DFU patient was dosed in August 2023. In March 2024, Aurealis Therapeutics announced the successful recruitment and randomization of half of the patients expected to participate in the study. The DIAMEND study is a multi-center, single-blinded, randomized, standard-of-care plus placebo-controlled study in patients with non-healing diabetic foot ulcers, conducted in Germany, Italy and Poland.

More details about our DIAMEND Phase 2 Clinical Study:
NIH National Library of Medicine record

PHASE 2 CLINICAL STUDIES IN VENOUS LEG ULCER AND PRESSURE ULCER WILL FOLLOW.

CHRONIC WOUNDS: AUP-16

Aurealis Therapeutics Pipeline Chronic Wounds

CHRONIC WOUNDS | AUP-16

Modality | Product Discovery In vivo POC GLP, S&T, CMC IND/CTA Phase 1 Phase 2 Phase 3 NDA/MAA
Diabetic Foot Ulcer
Venous Leg Ulcer
Pressure Ulcer

Do you want to knoW more about our lead asset aup-16?